Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'
Tweet Send to a Friend
Citi analyst David Lebowitz reiterated a Neutral rating and $31.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments "Following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
